7 minute read
Oct. 14, 2022
New FDA Approval: Deucravacitinib (Sotyktu), a First-In-Class Oral, Allosteric Tyrosine Kinase 2 Inhibitor
In September 2022, deucravacitinib (Sotyktu), a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, was approved by the FDA. Aside from its first-in-class mechanism of action, it is the first approved de novo deuterated drug.
This premium deep dive into deucravacitinib includes:
the industry context
the clinical data
the target rationale
the mechanism of action
the drug’s origins
See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.
Loading...